Dermatol. praxi. 2021;15(2):98-101 | DOI: 10.36290/der.2021.019
Bullous pemphigoid unwanted effect new oral diabetes drugs
- Kožní oddělení, Masarykova nemocnice v Ústí nad Labem
Association between the development of bullous pemphigoid and the use of some medicinal products, such as diuretics (spironolactone, furosemide) or some neuroleptics, is well documented in the literature. New oral diabetes drugs of glyptin type or inhibitors of dipeptidylpeptidase have expended this spectrum in recent years. Since 2018, 4 patiens with bullous dermatosis have been hospitalized in our dermatology department while taking linagliptin. This article aims to draw the attention of medical community to a possible increased incidence of bullous pemphigoid among diabetics patients who are treated with gliptins.
Keywords: blistering skin disorders, pemphigoid, linagliptin
Published: September 2, 2021 Show citation
References
- Štork J. Dermatovenerologie, druhé vydání. Galén 2013.
- Jedličková H. Autoimunitní bulózní dermatózy. In: Benáková N, a kol. Moderní farmakoterapie v dermatologii. Maxdorf 2020; 239-262.
- Salavec M. Pemphigoid bullosus. In: Hercogová J, et al. Klinická dermatovenerologie, 1. díl. Mladá fronta 2019; 362-368.
- Pemphigus, pemphigoid. [online]. Dostupné z: https://www.derm.cz/napln/historicke-standardy-cds/pemphigus-pemphigoid/
- Salavec M. Diagnostika a terapie autoimunitních puchýřnatých chorob. Dermatol. praxi 2010; 4(3): 148-155.
- Hertl M. Epidermale Struktur und Adhasionsmolekule. Fortschritte der praktischen Dermatologie und Venerologie 2004. Springer Verlag, 2005: 279-285.
Go to original source... - Prázný M. Účinnost a bezpečnost linagliptinu - význam pro klinickou praxi. Interní Med. 2014; 16(2): 62-66.
- Slíva J. Zakladní farmakologie inhibitorů dipeptidylpeptidazy-4. Farmakoterapie 2015; 11(1): 139-142.
- Souhrn údajů o přípravku. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/trajenta-epar-product-information_cs.pdf
- Haber R, Fayed AD, et al. Bullous Pemphigoid Associated With Linagliptin Treatment. JAMA Dermatol. 2016; 152(2): 224-226. Go to original source...
Go to PubMed... - Doležalová B, Flekač M. Linagliptin - diabetes bezpečně pod kontrolou již od začátku. Interní med. 2016; 18(2): 97-99. Go to original source...
- Sakai A, Shimomura Y, Ansai O, et al. Linagliptin - associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180. Br J Dermatolog. february 2017; 176: 541-543. Go to original source... Go to PubMed...
- Esposito I, Moretta G, Peris K, De Simone C. Linagliptin-induced bullous pemphigoid. Internacional Journal of Dermatology 2017; 56(12): 1467-1469. Go to original source... Go to PubMed...